ALGS · CIK 0001799448 · operating
Aligos Therapeutics is a clinical-stage biopharmaceutical company developing small molecules, oligonucleotide-based drugs, and viral protease inhibitors targeting viral and liver diseases. The company's pipeline spans multiple therapeutic areas, including a Phase 2a THR-β agonist (ALG-055009) for non-alcoholic steatohepatitis, a capsid assembly modulator (ALG-000184) in Phase 1b for chronic hepatitis B, a siRNA candidate (ALG-125755) in Phase 1 for hepatitis B, and a coronavirus protease inhibitor (ALG-097558) in Phase 2 development.
The company has established licensing and research collaborations with established pharmaceutical and academic partners, including Merck for oligonucleotide discovery in NASH, Emory University for hepatitis B capsid assembly technology, Luxna Biotech for hepatitis B-targeted oligonucleotides, and Katholieke Universiteit Leuven for coronavirus protease inhibitor development. Aligos also maintains a clinical collaboration with Xiamen Amoytop Biotech.
Aligos operates with approximately 70 full-time employees and is headquartered in South San Francisco, California. The company was incorporated in Delaware in 2018 and is listed on the Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-20.94 | $-20.94 | -1439.7% | |
| 2023 | $-1.36 | $-1.36 | — | |
| 2022 | — | — | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |